Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study

International Journal of Cardiology

Volumn 181, Issue , 2015, Pages 200-206

  Chen, Dong Yi ^a   Wang, Szu Heng ^a   Mao, Chun Tai ^a,b   Tsai, Ming Lung ^a   Lin, Yu Sheng ^a,b   Chou, Chung Chuan ^a   Wen, Ming Shien ^a   Wang, Chun Chieh ^a   Hsieh, I Chang ^a   Hung, Kuo Chun ^a   Chen, Tien Hsing ^a,c  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c Chang Gung Memorial Hospital   (China)

Author keywords

Chronic kidney disease; Dipeptidyl peptidase 4 (DPP 4) inhibitor; End stage renal disease; Myocardial infarction; Sitagliptin

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; SITAGLIPTIN;

AGED; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH SURVEY; HOSPITAL DISCHARGE; HUMAN; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RENAL INSUFFICIENCY, CHRONIC; TAIWAN; TREATMENT OUTCOME; TRENDS;

AGED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PATIENT DISCHARGE; POPULATION SURVEILLANCE; RENAL INSUFFICIENCY, CHRONIC; SITAGLIPTIN PHOSPHATE; TAIWAN; TREATMENT OUTCOME;

EID: 84947201480     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.12.029     Document Type: Article

References (29)

1. J.B. Meigs Epidemiology of cardiovascular complications in type 2 diabetes mellitus Acta Diabetol. 40 Suppl. 2 2003 S358 S361
2. S.R. Preis, S.J. Hwang, S. Coady, M.J. Pencina, R.B. D'Agostino Sr., and P.J. Savage Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005 Circulation 119 13 2009 1728 1735
3. C.A. Schneider, E. Ferrannini, R. Defronzo, G. Schernthaner, J. Yates, and E. Erdmann Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease J. Am. Soc. Nephrol. 19 1 2008 182 187
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 9131 1998 837 853
5. A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, and M. Woodward Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N. Engl. J. Med. 358 24 2008 2560 2572
6. H.C. Gerstein, M.E. Miller, S. Genuth, F. Ismail-Beigi, J.B. Buse, and D.C. Goff Jr. Long-term effects of intensive glucose lowering on cardiovascular outcomes N. Engl. J. Med. 364 9 2011 818 828
7. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease Am. J. Kidney Dis. 49 2 Suppl. 2 2007 S12 S154
8. S.E. Inzucchi Oral antihyperglycemic therapy for type 2 diabetes: scientific review JAMA 287 3 2002 360 372
9. J. Krepinsky, A.J. Ingram, and C.M. Clase Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease Am. J. Kidney Dis. 35 3 2000 500 505
10. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 356 24 2007 2457 2471
11. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 9548 2006 1696 1705
12. H.R. Patil, F.J. Al Badarin, H.A. Al Shami, S.K. Bhatti, C.J. Lavie, and D.S. Bell Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus Am. J. Cardiol. 110 6 2012 826 833
13. N.M. Scheller, U.M. Mogensen, C. Andersson, A. Vaag, and C. Torp-Pedersen All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population Diabetes Obes. Metab. 16 3 2014 231 236
14. D.T. Eurich, S. Simpson, A. Senthilselvan, C.V. Asche, J.K. Sandhu-Minhas, and F.A. McAlister Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study BMJ 346 2013 f2267
15. M. Ayaori, N. Iwakami, H. Uto-Kondo, H. Sato, M. Sasaki, and T. Komatsu Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients J. Am. Heart Assoc. 2 1 2013 e003277
16. P.A. Krijnen, N.E. Hahn, I. Kholova, U. Baylan, J.A. Sipkens, and F.P. van Alphen Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients Basic Res. Cardiol. 107 1 2012 233
17. J.C. Arjona Ferreira, M. Marre, N. Barzilai, H. Guo, G.T. Golm, and C.M. Sisk Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency Diabetes Care 36 5 2013 1067 1073
18. J.C. Arjona Ferreira, D. Corry, C.E. Mogensen, L. Sloan, L. Xu, and G.T. Golm Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial Am. J. Kidney Dis. 61 4 2013 579 587
19. C.L. Cheng, Y.H. Kao, S.J. Lin, C.H. Lee, and M.L. Lai Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan Pharmacoepidemiol. Drug Saf. 20 3 2011 236 242
20. C.H. Chang, Y.C. Lee, C.T. Tsai, S.N. Chang, Y.H. Chung, and M.S. Lin Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease Atherosclerosis 232 1 2014 224 230
21. W.C. Winkelmayer, S. Schneeweiss, H. Mogun, A.R. Patrick, J. Avorn, and D.H. Solomon Identification of individuals with CKD from Medicare claims data: a validation study Am. J. Kidney Dis. 46 2 2005 225 232
22. C.L. Cheng, C.H. Lee, P.S. Chen, Y.H. Li, S.J. Lin, and Y.H. Yang Validation of acute myocardial infarction cases in the National Health Insurance Research Database in Taiwan J. Epidemiol. 24 6 2014 500 507
23. Administration FaD Standardized Definitions for End Point Events in Cardiovascular Trials 2010 37
24. C.Y. Wu, Y.J. Chen, H.J. Ho, Y.C. Hsu, K.N. Kuo, and M.S. Wu Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection JAMA 308 18 2012 1906 1914
25. W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, and G.L. Bakris Alogliptin after acute coronary syndrome in patients with type 2 diabetes N. Engl. J. Med. 369 14 2013 1327 1335
26. B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, and B. Hirshberg Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus N. Engl. J. Med. 369 14 2013 1317 1326
27. J.B. Green, M.A. Bethel, S.K. Paul, A. Ring, K.D. Kaufman, and D.R. Shapiro Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease Am. Heart J. 166 6 2013 983 989 (e7)
28. J. Matsubara, S. Sugiyama, E. Akiyama, S. Iwashita, H. Kurokawa, and K. Ohba Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes Circ. J. 77 5 2013 1337 1344
29. A.J. Tremblay, B. Lamarche, C.F. Deacon, S.J. Weisnagel, and P. Couture Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes Metab. Clin. Exp. 63 9 2014 1141 1148